262 related articles for article (PubMed ID: 15900093)
1. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients.
Hampl H; Hennig L; Rosenberger C; Amirkhalily M; Gogoll L; Riedel E; Scherhag A
Am J Nephrol; 2005; 25(3):211-20. PubMed ID: 15900093
[TBL] [Abstract][Full Text] [Related]
2. Proven strategies to reduce cardiovascular mortality in hemodialysis patients.
Hampl H; Hennig L; Rosenberger C; Gogoll L; Riedel E; Scherhag A
Blood Purif; 2006; 24(1):100-6. PubMed ID: 16361849
[TBL] [Abstract][Full Text] [Related]
3. Optimized heart failure therapy and complete anemia correction on left-ventricular hypertrophy in nondiabetic and diabetic patients undergoing hemodialysis.
Hampl H; Hennig L; Rosenberger C; Gogoll L; Riedel E; Scherhag A
Kidney Blood Press Res; 2005; 28(5-6):353-62. PubMed ID: 16534231
[TBL] [Abstract][Full Text] [Related]
4. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
5. Regression of left ventricular hypertrophy in hemodialysis patients is possible.
Hampl H; Sternberg C; Berweck S; Lange D; Lorenz F; Pohle C; Riedel E; Gogoll L; Hennig L
Clin Nephrol; 2002 Jul; 58 Suppl 1():S73-96. PubMed ID: 12227731
[TBL] [Abstract][Full Text] [Related]
6. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
7. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.
Levin A; Djurdjev O; Thompson C; Barrett B; Ethier J; Carlisle E; Barre P; Magner P; Muirhead N; Tobe S; Tam P; Wadgymar JA; Kappel J; Holland D; Pichette V; Shoker A; Soltys G; Verrelli M; Singer J
Am J Kidney Dis; 2005 Nov; 46(5):799-811. PubMed ID: 16253719
[TBL] [Abstract][Full Text] [Related]
8. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
[TBL] [Abstract][Full Text] [Related]
9. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study.
Pascual J; Teruel JL; Moya JL; Liaño F; Jiménez-Mena M; Ortuño J
Clin Nephrol; 1991 Jun; 35(6):280-7. PubMed ID: 1831414
[TBL] [Abstract][Full Text] [Related]
10. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
[TBL] [Abstract][Full Text] [Related]
11. [Improvement of left ventricular hypertrophy by anemic-correcting erythropoietin therapy in chronic renal insufficiency].
Jiang JP; Hou FF; Gao LZ; Pan YB; Yang NS; Chen W; Shu GY; Chen YM; Chen J; Peng WH; Wu JP; Yang ZM
Zhonghua Nei Ke Za Zhi; 2005 Jan; 44(1):25-9. PubMed ID: 15769393
[TBL] [Abstract][Full Text] [Related]
12. [Left ventricular hypertrophy in end-stage renal disease and its possible regression as a result of correction of anemia and arterial hypertension].
Dzgoeva FU; Gatagonova TM; Kadzaeva ZK; Khamitsaeva OV; Kochisova ZKh; Dzutseva AT; Bazaeva BG
Ter Arkh; 2011; 83(6):42-6. PubMed ID: 21786575
[TBL] [Abstract][Full Text] [Related]
13. Impact of anemia treatment for left ventricular hypertrophy using long-acting erythropoietin-stimulating agents from the pre-dialysis to maintenance dialysis period in patients with chronic kidney disease, retrospective longitudinal cohort study.
Io H; Muto M; Sasaki Y; Ishizaka M; Kano T; Fukuzaki H; Maeda T; Shimizu Y; Nakata J; Suzuki Y
BMC Nephrol; 2023 Mar; 24(1):74. PubMed ID: 36966289
[TBL] [Abstract][Full Text] [Related]
14. [Diastolic dysfunction in different types of left ventricular hypertrophy in patients with end-stage renal failure: impact of long-term erythropoietin therapy].
Dzgoeva FU; Gatagonova TM; Kadzaeva ZK; Khamitsaeva OV; Kochisova ZKh; Dzueva AT; Bazaeva BG; Bestaeva TL
Ter Arkh; 2013; 85(6):44-50. PubMed ID: 23866598
[TBL] [Abstract][Full Text] [Related]
15. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
[TBL] [Abstract][Full Text] [Related]
16. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis.
Chan CT; Floras JS; Miller JA; Richardson RM; Pierratos A
Kidney Int; 2002 Jun; 61(6):2235-9. PubMed ID: 12028465
[TBL] [Abstract][Full Text] [Related]
17. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure.
Singh NP; Chandrashekhar ; Nair M; Anuradha S; Kohli R; Agarwal SK
J Assoc Physicians India; 2000 Mar; 48(3):301-6. PubMed ID: 11229114
[TBL] [Abstract][Full Text] [Related]
18. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.
Ayus JC; Go AS; Valderrabano F; Verde E; de Vinuesa SG; Achinger SG; Lorenzo V; Arieff AI; Luño J;
Kidney Int; 2005 Aug; 68(2):788-95. PubMed ID: 16014057
[TBL] [Abstract][Full Text] [Related]
19. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
20. COMPLETE CORRECTION OF ANEMIA WITH RECORMON® (ERYTHROPOIETIN β) IN PATIENTS ON CHRONIC HEMODIALYSIS.
Dimković N; Mitić I; Andrić B; Lilić Havidža B; Jelačić R; Milić N
Med Pregl; 2015; 68(9-10):324-30. PubMed ID: 26727829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
